Financial Performance - Operating revenue rose by 5.50% to CNY 273,965,712.41 year-on-year[5] - Net profit attributable to shareholders decreased by 46.82% to CNY 35,106,454.53 compared to the same period last year[5] - Basic and diluted earnings per share fell by 44.44% to CNY 0.05[6] - Total operating revenue for Q1 2021 was RMB 273,965,712.41, an increase of 5.0% compared to RMB 259,671,544.21 in Q1 2020[22] - Net profit for Q1 2021 was RMB 35,106,454.53, a decrease of 46.8% from RMB 66,010,410.51 in Q1 2020[23] - The company reported a total profit of RMB 43,131,295.28 for Q1 2021, down from RMB 73,023,092.88 in Q1 2020[23] Cash Flow - Net cash flow from operating activities improved significantly, reaching CNY 34,742,917.54, a 825.23% increase from the previous year[5] - In Q1 2021, the company reported cash inflow from operating activities of CNY 269,021,109.95, a decrease of 8.6% compared to CNY 294,345,745.49 in Q1 2020[28] - The net cash flow from operating activities was CNY 34,742,917.54, a significant improvement from a net outflow of CNY -4,790,579.65 in the same period last year[28] - Cash inflow from financing activities was CNY 80,000,000.00, down from CNY 100,000,000.00 in Q1 2020[29] - The net cash flow from financing activities was CNY -24,047,255.74, a decline from CNY 97,804,486.10 in the previous year[29] Assets and Liabilities - Total assets increased by 1.27% to CNY 2,750,705,857.95 compared to the end of the previous year[5] - Current liabilities decreased to CNY 713,339,802.26 from CNY 731,573,231.95, a reduction of 2.93%[15] - Non-current liabilities rose to CNY 522,384,730.29 from CNY 504,760,441.43, an increase of 3.23%[16] - Total liabilities slightly decreased to CNY 1,235,724,532.55 from CNY 1,236,333,673.38, a decline of 0.05%[16] - Owner's equity increased to CNY 1,514,981,325.40 from CNY 1,479,874,870.87, reflecting a growth of 2.14%[16] Shareholder Information - The company had a total of 18,818 shareholders at the end of the reporting period[9] - The largest shareholder, Lingkang Holdings Group Co., Ltd., held 47.61% of the shares, with 339,652,800 shares pledged[9] Expenses - Research and development expenses fell by 42.13% to ¥2,583,719.31 from ¥4,465,058.74 year-over-year[12] - Financial expenses increased by 389.87% to ¥2,183,761.55, primarily due to higher interest expenses[12] - Other income dropped by 98.43% to ¥533,767.78, significantly lower than ¥33,992,050.26 in the previous year[12] - The company experienced a decrease in sales expenses, which were RMB 166,037,292.38 in Q1 2021 compared to RMB 155,947,597.30 in Q1 2020[22] Investment Activities - Cash received related to investment activities increased by 66.67% to ¥250,000,000.00 from ¥150,000,000.00[13] - Cash outflow from investing activities totaled CNY 792,607,518.96, compared to CNY 227,514,362.45 in Q1 2020, indicating a substantial increase in investment spending[29] - The net cash flow from investing activities was CNY -541,038,313.76, worsening from CNY -67,091,281.70 in Q1 2020[29] - Investment income improved by 524.83% to ¥348,319.39, compared to a loss of ¥81,990.06 in the prior year[12]
灵康药业(603669) - 2021 Q1 - 季度财报